GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Freeline Therapeutics Holdings PLC (NAS:FRLN) » Definitions » Capex-to-Operating-Income

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Capex-to-Operating-Income : 0.00 (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Freeline Therapeutics Holdings Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Freeline Therapeutics Holdings's Capital Expenditure for the three months ended in Sep. 2023 was $-0.01 Mil. Its Operating Income for the three months ended in Sep. 2023 was $-12.03 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Freeline Therapeutics Holdings Capex-to-Operating-Income Historical Data

The historical data trend for Freeline Therapeutics Holdings's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Freeline Therapeutics Holdings Capex-to-Operating-Income Chart

Freeline Therapeutics Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Capex-to-Operating-Income
- - - - -

Freeline Therapeutics Holdings Quarterly Data
Dec18 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Freeline Therapeutics Holdings's Capex-to-Operating-Income

For the Biotechnology subindustry, Freeline Therapeutics Holdings's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Freeline Therapeutics Holdings's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Freeline Therapeutics Holdings's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Freeline Therapeutics Holdings's Capex-to-Operating-Income falls into.



Freeline Therapeutics Holdings Capex-to-Operating-Income Calculation

Freeline Therapeutics Holdings's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-7.014) / -95.287
=N/A

Freeline Therapeutics Holdings's Capex-to-Operating-Income for the quarter that ended in Sep. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.006) / -12.028
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Freeline Therapeutics Holdings  (NAS:FRLN) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Freeline Therapeutics Holdings Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Freeline Therapeutics Holdings's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
Gunnels Wood Road, Sycamore House, Stevenage, Hertfordshire, GBR, SG1 2BP
Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.